Perindopril — Membership Pricing

Other medications in Heart & Cardiovascular

• Pindolol
• Pitavastatin
• Pravastatin
• Propafenone
• Quinapril
• Ramipril
• Ranolazine
• Riociguat

About Perindopril

Perindopril is a widely prescribed medication used to manage high blood pressure and certain heart conditions. Understanding its benefits and how to access it affordably is crucial for your health journey. With TheDrugClub, you can navigate your prescription needs with confidence, potentially saving on vital medications like perindopril and ensuring you get the care you need.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Perindopril is approved for (FDA label)

Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. (1.1) Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. (1.2) 1.1 Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. 1.2 Stable Coronary Artery Disease Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction.

Source: Read the full FDA label on DailyMed. Label effective date: March 13, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Perindopril (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.4) ] . WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue perindopril erbumine as soon as possible [see Warnings and Precautions (5.4) ] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [ see Warnings and Precautions (5.4) ] .

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Perindopril (FDA label)

2 mg tablet is white to off-white colored round biconvex, uncoated tablets, with debossing “D” on one side and “5” & “7” on either side of the breakline on another side. 4 mg tablet is white to off-white colored capsule shaped uncoated tablets, with debossing “D” on one side and “5” & “8” on either side of the breakline on another side. 8 mg tablet is white to off-white colored round biconvex uncoated tablets, with debossing “D” on one side and “5” & “9” on either side of breakline on another side. Tablets: 2 mg, 4 mg and 8 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Perindopril (FDA label)

Because clinical trials are conducted under widely varying conditions, adverse event rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Perindopril (FDA label)

Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes. [see Drug Interactions (7.8) ] Perindopril erbumine tablets are contraindicated in combination with neprilysin inhibitor (e.g., sacubitril). Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.1) ]. Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema. ( 4 , 5.1 ) Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes ( 4 , 7.8 ) Do not take a neprilysin inhibitor with perindopril erbumine tablets ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Perindopril (FDA label)

Watch for anaphylactoid reactions, including angioedema. (5.1) Monitor renal function during therapy. (5.5) Assess for hypotension and hyperkalemia. (5.2 , 5.6) 5.1 Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including perindopril erbumine) may be subject to a variety of adverse events, some of them serious. Black patients receiving ACE inhibitors have a higher incidence of angioedema compared to nonblacks. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis, or larynx has been reported in patients treated with ACE inhibitors, including perindopril erbumine (0.1% of patients treated with perindopril erbumine in U.S. clinical trials). Angioedema associated with involvement of the tongue, glottis or larynx may be fatal. In such cases, discontinue perindopril erbumine treatment immediately and observe until the swelling disappears.

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Perindopril (FDA label)

Diuretics: Excessive drop in blood pressure. (7.1) Potassium-Sparing Diuretics/Potassium Supplements: Hyperkalemia. (7.2) Lithium: Increase serum lithium levels, symptoms of lithium toxicity. (7.3) Injectable Gold: Nitritoid reactions (facial flushing, nausea, vomiting, and hypotension). (7.4) NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect. (7.7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. ( 7.8 ) Neprilysin Inhibitor: risk of angioedema ( 7 ). 7.1 Diuretics Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of perindopril erbumine therapy. The possibility of hypotensive effects can be minimized by either decreasing the dose of or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.

Source: FDA prescribing information (DailyMed). Set ID: 87768fbf-7c63-47da-8925-0316f343d6ef. SPL document ID: 46f1c769-2a77-4526-8303-0abc4a78d53e. Label effective date: March 13, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.